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A B S T R A C T
Background: Cholera is known to be transmitted from person to person, and inactivated oral cholera
vaccines (OCVs) have been shown to confer herd protection via interruption of this transmission.
However, the geographic dimensions of chains of person-to-person transmission of cholera are
uncertain. The ability of OCVs to confer herd protection was used to deﬁne these dimensions in two
cholera-endemic settings, one in rural Bangladesh and the other in urban India.
Methods: Two large randomized, placebo-controlled trials of inactivated OCVs, one in rural Matlab,
Bangladesh and the other in urban Kolkata, India, were reanalyzed. Vaccine herd protection was
evaluated by relating the risk of cholera in placebo recipients to vaccine coverage of surrounding
residents residing within concentric rings. In Matlab, concentric rings in 100-m increments up to 700 m
were evaluated; in Kolkata, 50-m increments up to 350 m were evaluated.
Results: One hundred and eight cholera cases among 24 667 placebo recipients were detected during
1 year of post-vaccination follow-up at Matlab; 128 cholera cases among 34 968 placebo recipients were
detected during 3 years of follow-up in Kolkata. Consistent inverse relationships were observed between
vaccine coverage of the ring and the risk of cholera in the central placebo recipient for rings with radii up
to 500 m in Matlab and up to 150 m in Kolkata.
Conclusions: These results suggest that the dimensions of chains of person-to-person transmission in
endemic settings can be quite large and may differ substantially from setting to setting. Using OCVs as
‘probes’ to deﬁne these dimensions can inform geographical targeting strategies for the deployment of
these vaccines in endemic settings.
© 2017 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Introduction
Killed oral cholera vaccines (OCVs) are now stockpiled by the
World Health Organization (WHO) and are recommended public
health tools for the control of cholera outbreaks (Martin et al.,
2012). It is generally accepted that the rational use of such vaccines,
either for epidemic or endemic cholera, will require that
vaccination be targeted to geographically circumscribed
populations at greatest risk of cholera. Knowledge of the
geographic dimensions of chains of person-to-person cholera
transmission will be important for effective geographic targeting,
as OCVs have been demonstrated to confer both direct protection
to vaccinees and herd protection to populations, the latter
operating via interruption of person-to-person transmission.
The geographic dimensions of chains of person-to-person
cholera transmission were estimated in this study. A geographic
information system (GIS)-based method that has been employed
previously to evaluate whether OCVs confer vaccine herd
protection was used (Ali et al., 2005). It was reasoned that because
vaccine herd protection results from interruption of person-to-* Corresponding author at: icddr,b, Dhaka, Bangladesh.
E-mail address: jclemens@icddrb.org (J. Clemens).
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person cholera transmission, delineation of the dimensions of OCV
herd protection should demarcate the dimensions of chains of
person-to-person transmission.
Methods
Overview
The vaccine herd protective effects of inactivated OCVs were
analyzed in two randomized, placebo-controlled trials, one in
Matlab, Bangladesh (Clemens et al., 1990) and the other in Kolkata,
India (Sur et al., 2009), using a GIS-based method (Ali et al., 2005;
Ali et al., 2013). In this approach, a ‘virtual cluster’ is deﬁned as
persons whose residences are within a speciﬁed radius of the
residence of each person under analysis (termed the ‘focal person’),
and the risk of cholera for each focal person under analysis is
related to the vaccine coverage in surrounding virtual clusters. An
inverse relationship suggests vaccine herd protection, and when
the focal person under analysis has received placebo, indirect
vaccine protection is measured (Ali et al., 2005; Ali et al., 2013;
Clemens et al., 2011). Conceptually, the maximum radius in which
indirect vaccine protection is demonstrated should demarcate the
geographical size of a surrounding population that puts an
unimmunized individual at risk of becoming infected via
person-to-person transmission. In this study, the indirect OCV
protection of each focal person (placebo recipient) by vaccination
in successive rings of persons in surrounding residences was
analyzed, thus identifying the dimensions of chains of person-to-
person cholera transmission in the two study settings.
OCV trials under analysis
The two randomized, placebo-controlled trials analyzed in this
study were conducted in rural Matlab, Bangladesh, an area
bisected by the Dhonagoda River, and in urban Kolkata, India,
comprising wards 29, 30, and 33 (Figure 1); these trials have been
described in detail elsewhere (Clemens et al., 1990; Sur et al., 2009;
Clemens et al., 1986). Dosing with inactivated OCV or placebo was
conducted in 1985 in Matlab and in 2006 in Kolkata. In Matlab,
children aged 2–14 years and non-pregnant female adults
(!15 years) were eligible to participate in the trial. In Kolkata,
non-pregnant persons aged !1 year were eligible. In Matlab,
eligible persons were individually randomized to a three-dose
regimen of an oral cholera toxin B subunit-killed whole cell
(BS-WC) vaccine, oral killed whole cell (WC)-only vaccine, or oral
placebo. In Kolkata, eligible persons were randomized by
residential dwelling to a two-dose regimen of an oral killed
WC-only vaccine or oral placebo.
Diarrhea surveillance
In Matlab, surveillance was conducted for all diarrheal patients
from the study area who attended either the International Centre
for Diarrhoeal Disease Research, Bangladesh (icddr,b) Matlab
hospital or two community-operated treatment centers. Diarrhea
was deﬁned as the presence of at least three loose or liquid motions
in the 24 h before presentation, or one to two or an indeterminate
number of loose or liquid stools in the 24 h before presentation
with at least two signs of dehydration (poor skin turgor, sunken
eyes, dry mucous membranes, weakened radial pulse) on
presentation. Stools or rectal swabs were collected from these
patients and were tested for Vibrio cholerae O1 using conventional
microbiological methods (Bopp et al., 1999).
In Kolkata, diarrhea surveillance was conducted in nine project
health clinics and two governmental hospitals. Diarrhea was
deﬁned as having three or more loose stools in the 24 h before
presentation, or one to two or an indeterminate number of loose or
liquid stools in the 24 h before presentation together with
moderate or severe dehydration, according to WHO criteria, on
presentation (WHO, 2005). Rectal swabs were collected from all
diarrheal patients and tested in the project laboratory for
V. cholerae O1 and V. cholerae O139 using conventional methods
(Bopp et al., 1999).
In both studies, cholera was deﬁned as non-bloody diarrhea in
which V. cholerae O1 was isolated. V. cholerae O139 was not isolated
in the Kolkata trial. In the present analyses, cholera cases occurring
during 1 year after the time of vaccination in Matlab and during 3
years after the time of vaccination in Kolkata were considered;
Figure 1. The study areas.
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these were both intervals in which indirect herd OCV protection
was demonstrated in the earlier analyses (Ali et al., 2005; Ali et al.,
2013).
Deﬁning virtual clusters
In the earlier published analyses of these trials (Ali et al., 2005;
Ali et al., 2013), a statistical criterion was used to deﬁne the radius
around each placebo recipient to demarcate the virtual cluster of
people for determination of vaccine coverage. This criterion was
related to the variability of the variances of vaccine coverage across
virtual clusters, and was not based on whether vaccine coverage
was inversely related to the risk of cholera. This criterion yielded a
radius of 500 m for Matlab and 250 m for Kolkata.
In the present analyses, virtual clusters were deﬁned a priori as
concentric rings of residential populations in 100-m increments up
to 700 m (seven rings centering each placebo recipient) in Matlab,
and in 50-m increments up to 350 m (also seven rings centering
each placebo recipient) in Kolkata. The difference in the size of
increments was related to the dispersed population in Matlab
versus the congested urban setting in Kolkata. Vaccine coverage in
each ring was computed as the number of recipients of at least two
doses of vaccine divided by the number of all eligible residents at
the time of the ﬁrst dose.
Statistical analysis
The earlier analyses found no design effect due to the residence-
based allocation in Kolkata; therefore this trial was analyzed as if it
had been individually randomized (Sur et al., 2009). Indirect
vaccine protection was assessed by relating the risk of cholera in
recipients of at least two doses of placebo (focal persons) to vaccine
coverage of the deﬁned rings around these recipients. In crude
analyses the relationship for each ring between the quintile of
vaccine coverage around each focal person (quintiles were
ascertained from the distribution of coverages for all rings of
the same radius) and the risk of cholera in the focal person, was
evaluated, and this relationship was assessed with the Cochran–
Armitage test for trend. In multivariable logistic regression models,
the relationship between the levels of vaccine coverage of the
deﬁned ring (expressed dimensionally and ﬁtted as an indepen-
dent variable) and the occurrence of cholera for each focal person
(the dependent variable) was assessed, controlling for potentially
confounding variables. Based on the ﬁndings of the earlier work,
candidate variables for inclusion as covariates in the models for
Matlab were age at the date of ﬁrst dose, distance to the icddr,b
hospital in Matlab, and distance to the Dhonagoda River. Age at
date of ﬁrst dose, sex, owning at least one luxury item, per-capita
household expenditure, washing hands with soap and water after
defecation, and living in an owned house were considered as
candidate covariates in the Kolkata models. To select the covariates
for the ﬁnal models, those candidate variables found to be
associated with the risk of cholera at p < 0.10 in the bivariate
models were included, and these were retained in the ﬁnal model if
they remained signiﬁcant at p < 0.20 in a backward elimination
process. Multivariable odds ratios (OR) relating each percentage
increase in vaccine coverage to the occurrence of cholera were
estimated by exponentiation of the coefﬁcient for the vaccine
coverage variable in the models; p-values and 95% conﬁdence
intervals (CI) for these OR were estimated using the standard errors
of these coefﬁcients. All p-values and 95% CI were two-sided.
Ethics
The project in Matlab was approved by the Ethical Review
Committees of the icddr,b, Dhaka, Bangladesh and WHO (Geneva).
The project in Kolkata was approved by the ethics committees of
the National Institute of Cholera and Enteric Diseases (NICED) and
the Health Ministry Screening Committee of India, and the
International Vaccine Institute Institutional Review Board. In-
formed consent was obtained from all participants in these studies.
Results
There were 124 035 individuals eligible for vaccination in
Matlab and 107 774 individuals eligible for vaccination in Kolkata.
Among these populations, 108 cholera cases occurred among
24 667 recipients of at least two doses of placebo during the 1 year
of follow-up in Matlab; 128 cholera cases occurred among 34 968
two-dose placebo recipients during the 3 years of follow-up in
Kolkata.
The previously published reports that evaluated vaccine
coverage from 0 m to 500 m around placebo recipients in Matlab
(Ali et al., 2005) and from 0 m to 250 m around placebo recipients
in Kolkata (Ali et al., 2013) each found signiﬁcant inverse
relationships between vaccine coverage and the risk of cholera
in placebo recipients (Table 1).
Cholera vaccine coverage for each concentric ring in the present
analysis is presented in Table 2. Average vaccine coverage in each
ring ranged from 41% to 45% in Matlab and from 26% to 30% in
Kolkata. In the crude analyses in Matlab, a consistent inverse
relationship between the quintile of vaccine coverage within the
concentric ring and the risk of cholera in the focal person at the
center of the ring was observed for all rings with radii up to 500 m.
However, such a relationship was observed only for rings with radii
up to 200 m for focal persons in Kolkata (Table 3).
The backward elimination process for selecting covariates for
the ﬁnal model resulted in no covariates retained for Matlab and
only age retained for Kolkata. Multivariable logistic regression
models showed a signiﬁcant association between OCV coverage in
the ring and the risk of cholera in focal persons for rings with radii
up to 500 m in Matlab and up to 150 m for placebo recipients in
Table 1
Relationships between inactivated oral cholera vaccine coverage and the risk of cholera in placebo recipients in earlier published analyses (Ali et al., 2005; Ali et al., 2013).
Kolkata Matlab
HRa p-Value 95% CI ORb p-Value 95% CI
Cluster level cholera vaccine coverage 0.97 <0.0001 0.96–0.98 0.96 <0.0001 0.94–0.98
HR, hazard ratio; CI, conﬁdence interval; OR, odds ratio.
a Hazard ratio for the relative reduction in the risk of cholera for each percentage increase in vaccine coverage. Adjusted for age, sex, religion, distance from household to
nearest river, distance from household to nearest treatment center (kilometers), and experienced dysentery during follow-up.
b Odds ratio for the relative reduction in the rate of cholera for each percentage increase in vaccine coverage. Adjusted for age, individuals living in a larger cluster speciﬁed
in the stratiﬁcation, wards, monthly per-capita expenditure of the household, individuals living in a household always washing hands with soap and water after defecation,
individuals living in their own house, individuals living in a household owning at least one luxury item, and distance from the household to the nearest health clinic.
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Kolkata (Table 4). To assess whether the relationships between
OCV coverage and cholera risk in focal persons, by distance from
the focal person, could be explained simply by variations in
population density, population density was added as a covariate in
these models. Models that included population density as a
covariate again showed signiﬁcant inverse associations between
OCV coverage and the risk of cholera in focal persons for distances
up to 500 m in Matlab and 150 m in Kolkata.
Discussion
Using analyses of the indirect herd protection conferred by
OCVs as a probe to deﬁne the geographical dimensions of chains of
person-to-person transmission of cholera in Matlab, a rural site,
and Kolkata, an urban site, an inverse relationship was found
between vaccine coverage of the surrounding population and the
risk of cholera for placebo recipients for virtual clusters with radii
up to 500 m in Matlab and up to 150 m in Kolkata. These results
suggest that the dimensions of chains of person-to-person
transmission in endemic settings can be quite large and may
differ substantially from setting to setting.
Cholera has long been known to occur in geographic clusters.
Early studies of space–time clustering of cholera noted clustering
of cases within the same household or within small groups of
nearby households (Craig, 1988; Glass et al., 1983; Sugimoto et al.,
2014; Giebultowicz et al., 2011; Mosley et al., 1965; Philippines
Cholera Committee, 1970; Tamayo et al., 1965), leading to the
conventional wisdom that the person-to-person spread of cholera
is usually limited to household transmission. More recently, two
analyses performed in Matlab and Kolkata found an increased risk
of clinically signiﬁcant cholera shortly after the detection of index
cases for populations within 450 m of the residence of index cases
in Matlab, and within 50 m of residences of index cases in Kolkata
(Ali et al., 2016; Debes et al., 2016).
It is interesting to compare the present study estimates with
those of these more recent estimates, particularly since the present
study and the earlier studies were done at the same study sites (Ali
et al., 2016; Debes et al., 2016). All three analyses identiﬁed
surrounding populations much larger than the immediate
household or clusters of households as being relevant to cholera
transmission, and all identiﬁed substantially larger zones in the
rural Bangladesh site than in the urban India site. However, in
contrast to the two earlier analyses in Matlab and Kolkata, which
evaluated the population at risk for clinically signiﬁcant cholera
around identiﬁed cholera cases, regardless of the type of
transmission, the present study analyses speciﬁcally addressed
the size of surrounding zones in which the use of OCVs had a
demonstrable effect on person-to-person transmission.
Whether a simple proxy measure – population density – might
serve in lieu of analyses of OCV herd protection to deﬁne the
geographic dimensions of person-to-person transmission was
examined. However, inclusion of population density as an
additional covariate in the multivariable models failed to erase
the relationships between vaccine coverage and cholera risk in
focal persons, by distance from the focal person, indicating that
population density cannot be used as a simple proxy measure for
estimating the geographical dimensions of chains of person-to-
person transmission.
Several potential limitations of this analysis require discussion.
First, the impact of vaccine coverage calculated at the time that
vaccine doses were given was analyzed, rather than vaccine
coverage during post-vaccination follow-up, which would have
changed over time due to population births, deaths, and
migrations. Such misclassiﬁcation of coverage over time would
most likely have been non-differential with respect to the risk of
cholera and would have tended to make the estimates of the radii
of persons contributing to person-to-person transmission of
cholera conservative. Second, in the analyses the ORs were in
the range of 0.974–0.999 for Matlab and 0.949–0.996 for Kolkata,
which may seem modest in magnitude. However, it should be
appreciated that these ORs reﬂect relative reductions of risk of
cholera per one percentage increase in vaccine coverage. Third, for
simplicity, the analyses considered concentric circular geographic
rings of populations. It may be that zones of person-to-person
transmission in the two settings did not conform geometrically to
circles.
Fourth, although randomized clinical trials were analyzed, the
present analyses of herd protection were observational in design
and were subject to the limitations of such a non-randomized
design. Fifth, the maximum radius for herd protection may vary not
only from site to site, but also from vaccine to vaccine; had the
studies been performed with other cholera vaccines, the results
may have been different, depending on the capacity of the vaccines
studied to interrupt transmission. Nonetheless, the present
analyses are of relevance to the deployment of inactivated OCVs,
which are currently stockpiled by the WHO for deployment in
cholera-affected settings. Sixth, the analyses addressed cholera
occurring in endemic settings, in which the population has some
level of natural immunity; whether the ﬁndings can be generalized
to epidemic settings in immunologically naïve populations, where
the global OCV stockpile is occasionally deployed, is uncertain and
constitutes an important subject for future research. Finally,
caution should be exercised in generalizing the different geo-
graphical dimensions of person-to-person transmission in Kolkata
versus Dhaka to other urban versus rural areas. The Matlab and
Kolkata sites differed in multiple ways, not all of which were
related to their urban versus rural contexts.
This study has both theoretical and practical implications. The
maximum size of virtual clusters for which indirect vaccine
protection was detected in the two trials differed from the sizes of
virtual clusters that were analyzed in the earlier published
analyses of the trials, in which a radius for virtual clusters was
determined with an arbitrary statistical criterion (Ali et al., 2005;
Ali et al., 2013). This discrepancy suggests that work is required to
improve the earlier method for sizing virtual clusters in analyzing
vaccine herd protection. On the other hand, it was reassuring that
the present study analyses showed a pattern of declining vaccine
herd protection with increasing distance of the vaccinated
population from the central placebo recipient under analysis,
Table 2
Descriptive statistics for inactivated oral cholera vaccine coverage of populations
residing in the different concentric rings surrounding placebo recipients in the
Matlab (Bangladesh) and Kolkata (India) trials.
Ring size (meters) Mean % Median % Minimum % Maximum %
Matlab, Bangladesh
0–100 45.35 46.60 0 85.71
101–200 43.01 45.08 0 100.00
201–300 42.26 44.85 0 100.00
301–400 43.04 44.87 0 100.00
401–500 42.32 44.74 0 100.00
501–600 41.98 44.32 0 80.00
601–700 42.25 44.42 0 82.35
Kolkata, India
0–50 26.55 26.69 0 71.47
51–100 29.72 29.19 0 62.62
101–150 30.01 29.27 0 68.92
151–200 30.70 29.76 0 60.67
201–250 31.05 30.03 0 74.42
250–300 30.83 29.48 0 80.00
301–350 30.02 29.55 12.17 68.18
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providing evidence of the construct validity of the method. From a
practical perspective, the approach used herein may provide
guidance to geographically targeted OCV strategies for the control
of outbreaks of cholera occurring in endemic settings.
In summary, the results of this study suggest that the
dimensions of chains of person-to-person transmission in endemic
settings can be quite large and may differ substantially from setting
to setting. Using OCVs as ‘probes’ to deﬁne these dimensions can
Table 3
Risk of cholera among placebo recipients by quintile of vaccine coverage for each concentric ring around the placebo recipients in the Matlab (Bangladesh) and Kolkata (India)
trials.
Matlab Kolkata
% coverage by distance Placebo recipients Cases Risk/1000 % coverage by distance Placebo recipients Cases Risk/1000
0–100 m 0–50 m
"36.36 5389 30 5.57 "21.38 10 633 44 4.14
36.37–44.23 5089 25 4.91 21.39–27.33 7641 36 4.71
44.24–50.59 5057 24 4.75 27.34–32.55 6613 27 4.08
50.60–57.22 4841 19 3.92 32.56–40.49 5711 15 2.63
!57.23 4291 10 2.33 !40.50 4370 6 1.37
Z-statistic 2.43 2.81
(p-Value)a (0.0158) (0.0049)
101–200 m 51–100 m
"32.35 4911 30 6.11 "23.13 7059 38 5.38
32.36–41.67 4968 29 5.84 23.14–27.18 7410 35 4.72
41.68–48.51 4919 22 4.47 27.19–32.03 6995 22 3.15
48.52–55.42 5001 15 3.00 32.04–37.89 6755 21 3.11
!55.43 4868 12 2.47 !37.90 6749 12 1.78
Z-statistic 3.40 3.85
(p-Value)a (0.0007) (0.0001)
201–300 m 101–150 m
"30.86 4891 34 6.95 "24.65 7410 37 4.99
30.87–41.03 4978 24 4.82 24.66–28.04 7430 34 4.58
41.04–47.98 4962 15 3.02 28.05–31.57 7116 25 3.51
47.99–55.00 4962 25 5.04 31.58–36.05 6453 19 2.94
!55.01 4874 10 2.05 !36.06 6559 13 1.98
Z-statistic 3.20 3.34
(p-Value)a (0.0014) (0.0008)
301–400 m 151–200 m
"32.79 4882 27 5.53 "24.87 6900 40 5.80
32.80–41.51 4922 26 5.28 24.88–28.32 7332 24 3.27
41.52–47.97 4975 20 4.02 28.33–31.71 7066 19 2.69
47.98–54.48 4945 26 5.26 31.72–36.34 6519 22 3.37
!54.49 4943 9 1.82 !36.35 7151 23 3.22
Z-statistic 2.50 2.18
(p-Value)a (0.0125) (0.0292)
401–500 m 201–250 m
"32.77 4966 29 5.84 "25.26 6284 26 4.14
32.78–41.71 4968 27 5.43 25.27–28.10 7039 28 3.98
41.72–47.34 4940 25 5.06 28.11–31.21 6225 24 3.86
47.35–53.37 4952 17 3.43 31.22–35.35 7493 25 3.34
!53.38 4841 10 2.07 !35.36 7927 25 3.15
Z-statistic 3.20 1.16
(p-Value)a (0.0014) (0.24)
501–600 m 251–300 m
"32.39 4862 28 5.76 "25.70 6547 29 4.43
32.40–41.30 4923 14 2.84 25.71–28.23 7293 25 3.43
41.31–46.69 4940 18 3.64 28.24–30.86 6899 30 4.35
46.70–52.43 4927 29 5.89 30.87–35.12 6833 21 3.07
!52.44 5015 19 3.79 !35.13 7396 23 3.11
Z-statistic 0.30 1.28
(p-Value)a (0.78) (0.20)
601–700 m 301–350 m
"32.34 4827 21 4.35 "25.43 7134 23 3.22
32.35–41.27 5019 25 4.98 25.44–28.29 6827 22 3.22
41.28–47.01 4985 27 5.42 28.30–30.88 6887 29 4.21
47.02–52.99 4886 20 4.09 30.89–34.19 6881 30 4.36
!53.00 4950 15 3.03 !34.20 7239 24 3.32
Z-statistic 1.20 #0.56
(p-Value)a (0.24) (0.57)
a The Z-statistics and p-values were derived using the Cochran–Armitage trend test, as described in the Methods section.
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inform geographical targeting strategies for the deployment of
these vaccines in endemic settings.
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Table 4
Odds ratios relating the risk of cholera in placebo recipients to inactivated oral cholera vaccine coverage in successive concentric rings of populations in the Matlab
(Bangladesh) and Kolkata (India) trials.
Matlab Kolkata
Ring size (meters) ORa 95% CI p-Value Ring size (meters) ORa 95% CI p-Value
0–100 0.985 0.971–0.999 0.0330 0–50 0.984 0.970–0.999 0.0315
101–200 0.984 0.973–0.996 0.0076 51–100 0.974 0.957–0.993 0.0062
201–300 0.984 0.973–0.996 0.0070 101–150 0.972 0.949–0.996 0.0223
301–400 0.985 0.973–0.997 0.0182 151–200 0.989 0.965–1.013 0.3673
401–500 0.986 0.974–0.999 0.0283 201–250 1.002 0.978–1.028 0.8496
501–600 0.999 0.985–1.013 0.8695 251–300 0.979 0.951–1.007 0.1383
601–700 0.995 0.981–1.008 0.4343 301–350 1.004 0.973–1.035 0.8184
OR, odds ratio; CI, conﬁdence interval.
a Adjusted for age at the date of ﬁrst dose.
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